Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) EPS (Basic): 2011-2025

Historic EPS (Basic) for Capricor Therapeutics (CAPR) over the last 13 years, with Sep 2025 value amounting to -$0.54.

  • Capricor Therapeutics' EPS (Basic) fell 42.11% to -$0.54 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.56, marking a year-over-year decrease of 52.94%. This contributed to the annual value of -$1.15 for FY2024, which is 38.55% down from last year.
  • Latest data reveals that Capricor Therapeutics reported EPS (Basic) of -$0.54 as of Q3 2025, which was down 1.89% from -$0.53 recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' EPS (Basic) registered a high of $0.02 during Q4 2023, and its lowest value of -$0.54 during Q3 2025.
  • For the 3-year period, Capricor Therapeutics' EPS (Basic) averaged around -$0.31, with its median value being -$0.31 (2024).
  • Per our database at Business Quant, Capricor Therapeutics' EPS (Basic) surged by 106.45% in 2023 and then crashed by 650.00% in 2024.
  • Over the past 5 years, Capricor Therapeutics' EPS (Basic) (Quarterly) stood at -$0.26 in 2021, then decreased by 19.23% to -$0.31 in 2022, then surged by 106.45% to $0.02 in 2023, then plummeted by 650.00% to -$0.11 in 2024, then crashed by 42.11% to -$0.54 in 2025.
  • Its EPS (Basic) stands at -$0.54 for Q3 2025, versus -$0.53 for Q2 2025 and -$0.11 for Q4 2024.